Hurry up and wait: Is accelerated approval of new cancer drugs in the best interests of cancer patients?

Journal of Clinical Oncology

Volumn 21, Issue 20, 2003, Pages 3718-3720

  Schilsky, Richard L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; CAPECITABINE; DOCETAXEL; FLUOROPYRIMIDINE DERIVATIVE; GEFITINIB; IMATINIB; IRINOTECAN; OXALIPLATIN; RAZOXANE; TEMOZOLOMIDE;

CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT RESPONSE; METHODOLOGY; NOTE; TIME; UNITED STATES;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0142087631     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.942     Document Type: Editorial

References (20)

1. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration Approval of Oncology Drugs. J Clin Oncol 21:1404-1411, 2003
2. Hirschfeld S, Nagamura F, Keegan P: Food and Drug Administration with the accelerated approval program for oncology drugs. Proc Am Soc Clin Oncol 22:520, 2003 (abstr 2094)
3. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
4. Hillman SL, Sargent DJ, An M-W, et al: Evaluation of RECIST criteria in determining the response to treatment in solid tumors: A North Central Cancer Treatment Group investigation. Proc Am Soc Clin Oncol 22:521, 2003 (abstr 2095)
5. Buyse M, Thirion P, Carlson RW, et al: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Lancet 356:373-378, 2000
6. Chen TT, Chute JP, Feigal E, et al: A model to select chemotherapy regimens for phase III trials for extensive-stage small cell lung cancer. J Natl Cancer Inst 92:1601-1607, 2000
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000
8. Nabholtz J-M, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1424, 1999
9. O'Shaughnessy J, Miles D, Vukelja S, et al: Superior survival with capecitabine plus docetaxel therapy in anthracycline pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 20:2812-2823, 2002
10. Goldberg RM, Morton RF, Sargent DJ, et al: N9741: Oxaliplatin or CPT-11 plus 5-fluorouracil/leucovorin or oxaliplatin/CPT-11 in advanced colorectal cancer-Updated efficacy and quality of life data from an intergroup study. Proc Am Soc Clin Oncol 22:252, 2003 (abstr 1009)
11. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
12. Fumoleau P, Seidman AD, Trudeau ME, et al: Docetaxel: A new active agent in the therapy of metastatic breast cancer. Exp Opin Invest Drugs 6:1853-1865, 1997
13. United States Food and Drug Administration: Oncology Drugs Advisory Committee Meeting transcript. http://www.fda.gov/ohrms/dockets/ac/ 98/transcpt. Last accessed June 19, 2003
14. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 345:144, 2001 (letter)
15. Ladewski L, Blelknap SM, Nebeker JR: Dissemination of information of potentially fatal adverse drug reactions for cancer drugs: 2000 to 2002. J Clin Oncol 21:3859-3866, 2003
16. United States Food and Drug Administration: Oncology Drugs Advisory Committee Meeting transcript. http://www.fda.gov/ohrms/dockets/ac/ 03/transcpt/3936A1. Last accessed June 19, 2003
17. Fukuoka M, Yano S, Giaccone G, et al: A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21:2237-2246, 2003
18. Kris MG, Natale RB, Herbst R, et al: A phase II trial of ZD1839 in advanced non small cell lung cancer patients who had failed platinum and docetaxel-based regimens. Proc Am Soc Clin Oncol 21:292a, 2002 (abstr 1166)
19. Giaccone G, Johnson DH, Manegold C, et al: A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT-1). Ann Oncol 13:2, 2002 (abstr)
20. Johnson DH, Herbst R, Giaccone G, et al: ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): Initial results from a phase III trial (INTACT-2). Ann Oncol 13:127, 2002 (abstr)